Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

C4T raises $170m for human trials of degrader drugs

C4T has raised $170m from a Series B round and venture debt funding. This influx of capital will be used to move its four lead degrader drugs into clinical trials within the next couple of years.

Close
Close
Close

Go Top